Atossa Genetics Inc. to Present at the Rodman & Renshaw 17th Annual Global Investment Conference

SEATTLE, WA--(Marketwired - Sep 4, 2015) - Atossa Genetics Inc. (NASDAQ: ATOS), a healthcare company focused on improving breast health through the development of pharmaceuticals to treat breast health conditions and through commercialization of its medical devices and laboratory tests, today announced that it will be a featured presenter at the Rodman & Renshaw 17th Annual Global Investment Conference, on September 9, 2015 at the St. Regis Hotel in New York City.

Steven C. Quay, M.D., Ph.D., CEO and President of Atossa will present the company's business model and growth strategy at 5:05 to 05:30 PM in Louis XVI B (2nd floor). In addition, a live audio webcast of Dr. Quay's presentation can be accessed via the following link: http://wsw.com/webcast/rrshq25/atos.

The webcast will be archived for 90 days following the event and may be accessed via Atossa's website at http://ir.atossagenetics.com/ir-calendar.

The Rodman & Renshaw 17th Annual Global Investment Conference will be held September 9 and 10, 2015 at the St. Regis Hotel in New York City. For more information or to register for the conference, please visit the conference website at http://www.rodm.com.

Management will be available for one-on-one meetings throughout the conference.

About Atossa Genetics

Atossa Genetics Inc. is focused on improving breast health through the development of laboratory services, medical devices and therapeutics. The laboratory services are being developed by its subsidiary, The National Reference Laboratory for Breast Health Inc. The laboratory services and the company's medical devices are being developed so they can be used as companions to therapeutics to treat various breast health conditions. For more information, please visit www.atossagenetics.com.

Forward-Looking Statements

Forward-looking statements in this press release are subject to risks and uncertainties that may cause actual results to differ materially from the anticipated or estimated future results, including the risks and uncertainties associated with actions by the FDA, the outcome or timing of regulatory approvals needed by Atossa to sell its products, responses to regulatory matters, Atossa's ability to continue to manufacture and sell its products, recalls of products, the safety and efficacy of Atossa's products and services, performance of distributors and manufacturers, whether Atossa can launch in the United States and foreign markets the additional tests, devices and therapeutics in its pipeline in a timely and cost effective manner, and other risks detailed from time to time in Atossa's filings with the Securities and Exchange Commission, including without limitation its periodic reports on Form 10-K and 10-Q, each as amended and supplemented from time to time.